Shares of Stemline Therapeutics Inc. (NASDAQ:STML) rose 6.9% during trading on Tuesday . The stock traded as high as $8.85 and last traded at $7.91, with a volume of 1,109,139 shares trading hands. The stock had previously closed at $7.40.

STML has been the subject of several recent analyst reports. Jefferies Group restated a “buy” rating and issued a $23.00 price target on shares of Stemline Therapeutics in a report on Friday, July 22nd. Roth Capital reiterated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a report on Wednesday, July 6th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a report on Tuesday, June 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Stemline Therapeutics presently has a consensus rating of “Buy” and an average price target of $19.56.

The stock has a 50 day moving average price of $7.26 and a 200 day moving average price of $6.11. The stock’s market capitalization is $137.07 million.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities analysts expect that Stemline Therapeutics Inc. will post ($2.11) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Stemline Therapeutics stock. Royce & Associates LLC increased its stake in shares of Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned approximately 0.91% of Stemline Therapeutics worth $1,004,000 at the end of the most recent reporting period.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.